India's Cipla gets tentative US nod for HIV tablets
MUMBAI Oct 18 (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters. (Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Japan shares soar, yen skids after BOJ stuns with new easing steps
- Suspect in Pennsylvania police ambush captured after seven-week manhunt
- Oil price declines have small-cap shale investors scrambling
- Special Report: Tsunami evacuees caught in $30 billion Japan money trap